Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Dasatinib + Trametinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Dasatinib||Sprycel||BMS-354825||ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 28 BTK inhibitor 32 CSF1R Inhibitor 27 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 53 PDGFR Inhibitor (Pan) 27 SRC Inhibitor 31 TNK2 Inhibitor 6||Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov).|
|Trametinib||Mekinist||GSK1120212||MEK inhibitor (Pan) 23 MEK1 Inhibitor 22 MEK2 Inhibitor 20||Mekinist (trametinib) inhibits MEK 1 and 2, which potentially leads to reduced tumor cell proliferation (PMID: 27956260). Mekinist (trametinib) is FDA approved for melanoma patients harboring BRAF V600E or BRAF V600K mutations, and in combination with Tafinlar (dabrafinib) for BRAF V600E/K-mutant melanoma, BRAF V600E- mutant non-small cell lung cancer, BRAF V600E-mutant anaplastic thyroid cancer, and for adult and pediatric patients of 6 years or older with unresectable or metastatic solid tumors harboring BRAF V600E (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E||thyroid gland cancer||sensitive||Dasatinib + Trametinib||Preclinical - Cell culture||Actionable||In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).||27222538|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|